ALTRENO (nda209353)- (0.05%)

Generic Name	TRETINOIN	Innovator	DOW PHARM
Dosage	0.05%
ParaIV Filing	No	505(b)2 Filing	No
Last Patent Expiry	2038-Aug-22	NCE Excl Expiry	Expired
ODE Expiry	None	NP Expiry	None
GAIN Expiry	None	Drug Complexity	No
Indication	ALTRENO is a retinoid indicated for The the topical treatment of acne vulgaris in patients 9 years of age and older.

Approvals and Launches

Final Approvals	Tentative Approvals	Generic Launches
0	0	0

Other Developers

Total Other Developers	4

Drugs with Suitability

Drugs with Suitability	No

Drug Pricing

	NDA			ANDA
Dosage	Weekly	Monthly	Yearly	Yearly Up	Yearly Down
0.05%	**	**	-	-	-

Drug Sales

NDA Sales Available	Total Generic Sales Available
Yes	0

Manufacturing Details of ALTRENO